ELICITATION OF BROAD IMMUNITY USING VLPS WITH CONSENSUS ENVS

使用 VLPS 和共识 ENVS 诱导广泛免疫

• 批准号: 8173016
• 负责人: Preston A Marx
• 金额: $ 6.18万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8173016
• 关键词: Aftercare; Animals; Antibodies; Blood specimen; CD8-Positive T-Lymphocytes; CD8B1 gene; Computer Retrieval of Information on Scientific Projects Database; Consensus; Drops; Exhibits; Funding; Grant; Immune response; Immunity; Institution; Monitor; Plasma; Recovery; Research; Research Personnel; Resources; Sampling; Source; Time; United States National Institutes of Health; Viral; Viral Load result; follow-up

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Animals were sampled from May 2009  September 2009 as follow-up from viral challenge in March 2009. Samples were used to monitor immune response, plasma viral loads (PVL). In September 2009, ten of the original 16 animals were treated four times with anti-CD8 antibody. Prior to the anti-CD8 treatment, all ten animals had undetectable PVL (four animals never exhibited detectable viral loads, six animals had positive viral loads after challenge but were undetectable at least 21 days prior to treatment). Blood samples were collected through November 2009 to monitor CD8 levels, immune response and plasma viral loads. After treatment, all animals showed significant drops in CD8 levels followed by a slow recovery of CD8 cells. The PVL of five of the treated animals remained below detectable limits after treatment. Five of the animals exhibited a resurgence of plasma viral loads after anti-CD8 treatment (all had previously exhibited detectable viral loads after challenge). Within 30 days after anti-CD8 treatment, the PVL of these five animals returned to below detectable limits.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 从2009年5月开始对动物进行采样  2009年9月作为2009年3月病毒攻毒的随访。 样本用于监测免疫应答、血浆病毒载量（PVL）。 2009年9月，最初16只动物中的10只用抗CD 8抗体处理4次。 在抗CD 8处理前，所有10只动物均具有不可检测的PVL（4只动物从未表现出可检测的病毒载量，6只动物在攻毒后具有阳性病毒载量，但在处理前至少21天不可检测）。 在2009年11月之前采集血样，以监测CD 8水平、免疫应答和血浆病毒载量。 治疗后，所有动物均显示出CD 8水平显著下降，随后CD 8细胞缓慢恢复。 给药后，5只给药动物的PVL仍低于可检测限度。 5只动物在抗CD 8处理后表现出血浆病毒载量的复苏（所有动物在攻毒后先前均表现出可检测的病毒载量）。 在抗CD 8治疗后30天内，这5只动物的PVL恢复至低于检测限。